StockData
Amgen Inc logo

Amgen Inc (AMGN) stock

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$457.93−4.39 (-0.95%)

Close on Nov 17, 2026Market cap $247.57BP/E 26.5Yield 2.11%

Amgen total assets

Total assets on the balance sheet at the end of each period.

Amgen's total assets was $96.05B at Sep 30, 2026. For fiscal 2025 it was $90.59B, down 1.4% from the year before. Over ten years it grew 2.4% a year on average. The highest annual figure on record is $97.15B in fiscal 2023.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$90.59B-1.4%
FY2024Dec 31, 2024$91.84B-5.5%
FY2023Dec 31, 2023$97.15B+49.2%
FY2022Dec 31, 2022$65.12B+6.5%
FY2021Dec 31, 2021$61.17B-2.8%
FY2020Dec 31, 2020$62.95B+5.4%
FY2019Dec 31, 2019$59.71B-10.1%
FY2018Dec 31, 2018$66.42B-16.9%
FY2017Dec 31, 2017$79.95B+3.0%
FY2016Dec 31, 2016$77.63B+8.6%
FY2015Dec 31, 2015$71.45B+3.5%
FY2014Dec 31, 2014$69.01B+4.4%
FY2013Dec 31, 2013$66.13B+21.8%
FY2012Dec 31, 2012$54.30B+11.1%
FY2011Dec 31, 2011$48.87B+12.4%
FY2010Dec 31, 2010$43.49B+9.7%
FY2009Dec 31, 2009$39.63B+8.8%
FY2008Dec 31, 2008$36.43B–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$96.05B+6.6%
Q2 FY2026Jun 30, 2026$95.64B+8.8%
Q1 FY2026Mar 31, 2026$92.50B+3.5%
Q4 FY2025Dec 31, 2025$90.59B-1.4%
Q3 FY2025Sep 30, 2025$90.14B-0.8%
Q2 FY2025Jun 30, 2025$87.90B-3.3%
Q1 FY2025Mar 31, 2025$89.37B-3.9%
Q4 FY2024Dec 31, 2024$91.84B-5.5%
Q3 FY2024Sep 30, 2024$90.88B+0.4%
Q2 FY2024Jun 30, 2024$90.91B+0.7%
Q1 FY2024Mar 31, 2024$92.98B+4.8%
Q4 FY2023Dec 31, 2023$97.15B+49.2%
Q3 FY2023Sep 30, 2023$90.53B+42.1%
Q2 FY2023Jun 30, 2023$90.27B+52.2%
Q1 FY2023Mar 31, 2023$88.72B+49.9%
Q4 FY2022Dec 31, 2022$65.12B+6.5%
Q3 FY2022Sep 30, 2022$63.70B-2.0%
Q2 FY2022Jun 30, 2022$59.29B-5.2%
Q1 FY2022Mar 31, 2022$59.20B-6.0%
Q4 FY2021Dec 31, 2021$61.17B-5.4%
Q3 FY2021Sep 30, 2021$64.99B-0.0%
Q1 FY2021Mar 31, 2021$62.54B+1.4%
Q4 FY2020Dec 31, 2020$62.95B+5.4%
Q3 FY2020Sep 30, 2020$64.64B+8.9%
Q2 FY2020Jun 30, 2020$65.01B+1.6%
Q1 FY2020Mar 31, 2020$61.67B-7.1%
Q4 FY2019Dec 31, 2019$59.71B-11.3%
Q2 FY2019Jun 30, 2019$59.37B-12.3%
Q1 FY2019Mar 31, 2019$64.00B-10.1%
Q4 FY2018Dec 31, 2018$66.42B-16.9%
Q3 FY2018Sep 30, 2018$67.33B-16.2%
Q2 FY2018Jun 30, 2018$67.68B-15.0%
Q1 FY2018Mar 31, 2018$71.16B-8.6%
Q4 FY2017Dec 31, 2017$79.95B+3.0%
Q3 FY2017Sep 30, 2017$80.33B+2.8%
Q2 FY2017Jun 30, 2017$79.59B+5.5%
Q1 FY2017Mar 31, 2017$77.86B–
Q4 FY2016Dec 31, 2016$77.63B–
Q3 FY2016Sep 30, 2016$78.15B–
Q2 FY2016Jun 30, 2016$75.47B–

More Amgen figures

See a number that looks wrong?